UCB SA UCBJF
325.84 USD +8.27 (+2.60%)
At closeNov 6, 2026, 4:00 PM EST
321.00 Day range 321.00
231.75 52-week range 345.39
- YTD
- +10.99%
- 1 year
- +28.33%
- Market cap
- 62.13B
- EPS (ttm)
- 13.20
- P/E ratio
- 24.68
- YTD return
- +10.99%
- 1-year return
- +28.33%
- Volume
- 488
- Avg volume
- 321
- Open
- 321.00
- Previous close
- 317.57
- Day's range
- 321.00 – 321.00
- 52-week range
- 231.75 – 345.39
- Earnings date
- Feb 25, 2027
ALL +292.34 (+872.66%)
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 6.05.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 6.05 | — | — | — |
| Jul 30, 2026 | Jun 30, 2026 | 5.81 | 7.81 | +2.00 | +34.42% |
| Feb 26, 2026 | Dec 31, 2025 | 5.83 | 7.59 | +1.76 | +30.19% |
| Jul 31, 2025 | Jun 30, 2025 | 3.89 | 2.88 | -1.01 | -25.96% |
| Feb 27, 2025 | Dec 31, 2024 | 2.68 | 4.56 | +1.88 | +70.15% |
| Jul 25, 2024 | Jun 30, 2024 | 1.89 | 1.15 | -0.74 | -39.15% |
News
UCB Selects Veeva Vault CRM 
What's Going On with MoonLake Immunotherapeutics Stock on Thursday? 
Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle 
Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment 
J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline
Your note
Sign in to keep a note on UCBJF — it syncs with the Stock Master app.